Browsing by Author "Karadag, Omer"

Now showing 1 - 4 of 4

Assessment of Takayasu's Arteritis Patients with Indian Takayasu Clinical Activity Score (ITAS2010) Improves with the Incorporation of Imaging
(2014) Oner, Fatma Alibaz; Aydin, Sibel Zehra; Akar, Servet; Aksu, Kenan; Kamali, Sevil; Yucel, Eftal; Karadag, Omer; Ozer, Huseyin; Kiraz, Sedat; Onen, Fatos; Inanc, Murat; Keser, Gokhan; Akkoc, Nurullah; Direskeneli, Haner; F-8858-2011
Leflunomide As a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(2018) Kimyon, Gezmis; Kiraz, Sedat; Ertenli, Ihsan; Kucuksahin, Orhan; Dalkilic, Ediz; Bes, Cemal; Kanitez, Nilufer Alpay; Kasifoglu, Timucin; Emmungil, Hakan; Coskun, Belkis Nihan; Yagiz, Burcu; Koca, Suleyman Serdar; Cinar, Muhammet; Ates, Askin; Akar, Servet; Bakirli, Duygu Ersozlu; Yazisiz, Veli; Bilge, Nazife Sule Yasar; Tufan, Muge Aydin; Karadag, Omer; Kelesoglu, Ayse Bahar; Mercan, Ridvan; Gercik, Onay; Oz, Burak; Akar, Zeynel Abidin; Yilmaz, Sedat; Turan, Sezin; Pehlivan, Yavuz; Terzioglu, Ender; Kilic, Levent; Erten, Sukran; Tekgoz, Emre; Tascilar, Koray; Kalyoncu, Umut; https://orcid.org/0000-0003-1537-2192; W-3342-2017
Methodology of a new inflammatory arthritis registry: TReasure
(2018) Tufan, Muge Aydin; Kalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali Ihsan; Dalkilic, Huseyin Ediz; Bes, Cemal; Kucuksahin, Orhan; Kasifoglu, Timucin; Alpay Kanitez, Nilufer; Emmungil, Hakan; Kimyon, Gezmis; Yasar Bilge, Nafize Sule; Akar, Servet; Atagunduz, Mehmet Pamir; Koca, Suleyman Serdar; Ates, Askin; Yazisiz, Veli; Terzioglu, Ender; Ersozlu, Emine Duygu; Tufan, Muge Aydin; Cinar, Muhammet; Mercan, Ridvan; Sahin, Ali; Erten, Sukran; Pehlivan, Yavuz; Yilmaz, Sedat; Kelesoglu Dincer, Ayse Bahar; Gercik, Onay; Coskun, Belkis Nihan; Yagiz, Burcu; Kaymaz Tahra, Sema; Aksoy, Aysun; Karadag, Omer; Kilic, Levent; Kiraz, Sedat; 30119164
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients. Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of the database is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies that operate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support the TReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure) with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features, comorbidities, radiology and laboratory results, measures of disease activity, and treatment data. Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of the patients currently receiving these treatments, and retrospective data as much as allowed by the participating centers' records. Finally, a high-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
Viral hepatitis screening guideline before biological drug use in rheumatic patients
(2016) Karadag, Omer; Kasifoglu, Timucin; Ozer, Birol; Kaymakoglu, Sabahattin; Kus, Yesim; Inanc, Murat; Keser, Gokhan; Kiraz, Sedat; 27708965
Biological drugs (tumor necrosis factor inhibitors, rituximab, tocilizumab, abatacept, and tofacitinib) are important treatment alternatives in rheumatology, particularly for resistant patients. However, they may cause hepatitis B virus (HBV) and hepatitis C virus (HCV) reactivation; for instance, HBV reactivation may occur in a patient who is an inactive hepatitis B surface antigen (HBsAg) carrier or who has resolved HBV infection. Therefore, the screening of patients before biological treatment and the application of a prophylactic treatment, particularly with respect to latent HBV infections, are recommended when necessary. This guideline covers pre-treatment screening and follow-up recommendations, if required, with respect to viral hepatitides in rheumatology patients who are planned to be given biological drugs. Although this guideline is prepared for biological disease-modifying antirheumatic drugs (DMARDs), it is recommended to be used also for target-oriented DMARDS and medium-high dose corticosteroids (>7.5 mg prednisolone/day equivalent). It should be considered that the reactivation risk is higher when more than one immunosuppressive drug is used.